PROTAGONIST THERAPEUTICS INC's ticker is PTGX and the CUSIP is 74366E102. A total of 137 filers reported holding PROTAGONIST THERAPEUTICS INC in Q2 2022. The put-call ratio across all filers is 0.19 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $13,810 | -99.9% | 500,000 | -37.5% | 0.43% | -46.0% |
| Q1 2022 | $18,946,000 | -55.7% | 800,100 | -36.0% | 0.79% | -31.6% |
| Q4 2021 | $42,750,000 | +60.8% | 1,250,000 | -16.7% | 1.16% | +95.0% |
| Q3 2021 | $26,580,000 | +1268.0% | 1,500,000 | +1900.0% | 0.60% | +1650.0% |
| Q1 2021 | $1,943,000 | -27.5% | 75,000 | -43.6% | 0.03% | -41.4% |
| Q4 2020 | $2,681,000 | +3.1% | 133,000 | 0.0% | 0.06% | -7.9% |
| Q3 2020 | $2,600,000 | +5.2% | 133,000 | -5.0% | 0.06% | -8.7% |
| Q2 2020 | $2,472,000 | – | 140,000 | – | 0.07% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JOHNSON & JOHNSON | 2,449,183 | $19,373,000 | 4.95% |
| Bain Capital Life Sciences Investors, LLC | 2,260,572 | $17,881,000 | 2.10% |
| Finepoint Capital LP | 735,126 | $5,815,000 | 2.01% |
| Altium Capital Management LP | 365,100 | $2,888,000 | 1.16% |
| RTW INVESTMENTS, LP | 4,794,499 | $37,924,000 | 0.98% |
| Amitell Capital Pte Ltd | 50,129 | $397,000 | 0.90% |
| COWEN AND COMPANY, LLC | 1,065,724 | $8,430,000 | 0.81% |
| Tri Locum Partners LP | 155,000 | $1,226,000 | 0.50% |
| BVF INC/IL | 1,106,838 | $8,755,000 | 0.42% |
| HighVista Strategies LLC | 46,459 | $367,000 | 0.22% |